NCT02265367View on ClinicalTrials.gov

Novel Medication as a Potential Smoking Cessation Aid

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Tobacco Use Disorder
Interventions
DRUG

Levomilnacipran

DRUG

Placebo

Trial Locations (1)

55455

Clinical and Translational Sciences Institute, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02265367 - Novel Medication as a Potential Smoking Cessation Aid | Biotech Hunter | Biotech Hunter